BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Isarna Therapeutics 

Josef-Engert-Strasse 9

Regensburg    D-93053  Germany
Phone: 49-941-9201-30 Fax: 49-941-9201-329


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Isarna Therapeutics Enters Into A Strategic Manufacturing Agreement With Sanofi (France) (SAN.PA) 1/9/2014 12:50:53 PM    More...
Isarna Therapeutics And Santaris Pharma A/S Announce License Agreement For The Development Of Next Generation Oligonucleotides To Treat TGF-Beta-Mediated Diseases 1/8/2014 9:52:47 AM    More...
Antisense Pharma Changes Name to Isarna Therapeutics 9/30/2013 9:42:35 AM    More...
ANTISENSE PHARMA GmbH Announces Revised Development Path for Trabedersen 2/26/2013 11:14:38 AM    More...
ANTISENSE PHARMA GmbH Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma 7/24/2012 9:52:34 AM    More...
ANTISENSE PHARMA GmbH Presents Trabedersen Phase I/II Complete Data at American Society of Clinical Oncology 6/4/2012 10:42:35 AM    More...
Dr. Philippe Calais Appointed Chief Executive Officer of ANTISENSE PHARMA GmbH 5/10/2012 6:25:45 AM    More...
ANTISENSE PHARMA GmbH Special Issue: Transforming Growth Factor Beta (TGF-ß) as a Target in Oncology 1/11/2012 10:02:31 AM    More...
ANTISENSE PHARMA GmbH Completes Round of Financing Worth Approximately 8 Million Euro - Founding Shareholders Facilitate the Participation of New Investors 7/6/2011 1:28:44 PM    More...
ANTISENSE PHARMA GmbH's Trabedersen Showed Excellent Safety Profile and First Signals of Encouraging Efficacy in Solid Tumors 6/7/2011 10:01:17 AM    More...
1234